Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 22; no. 1; p. 1348
Main Authors Allahyari, Abolghasem, Ehsanpour, Ali, Najafi, Behrouz, Ansarinejad, Nafseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kaf, Hamidreza, Najaf, Safa
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.12.2022
BioMed Central
BMC
Online AccessGet full text

Cover

More Information
Bibliography:correction
SourceType-Other Sources-1
content type line 63
ObjectType-Correction/Retraction-1
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-022-10455-0